Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study – ANNALS OF ONCOLOGY

Passaro, A; Wang, J; Wang, Y; Lee, SH; Melosky, B; Shih, JY; Wang, J; Azuma, K; Juan-Vidal, O; Cobo, M; Felip, E; Girard, N; Cortot, AB; Califano, R; Cappuzzo, F; Owen, S; Popat, S; Tan, JL; Salinas, J; Tomasini, P; Gentzler, RD; William, WN Jr; Reckamp, KL;...

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA – ANNALS OF ONCOLOGY

Felip, E; Cho, BC; Gutiérrez, ; Alip, A; Besse, B; Lu, S; Spira, AI; Girard, N; Califano, R; Gadgeel, SM; Yang, JCH; Yamamoto, S; Azuma, K; Kim, YJ; Lee, KH; Danchaivijitr, P; Ferreira, CG; Cheng, Y; Sendur, MAN; Chang, GC; Wang, CC; Prabhash, K; Shinno, Y;...

An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer’s Disease Cognitive Decline Altering the Microglial Response – JOURNAL OF ALZHEIMERS DISEASE

García-Alberca, JM; de Rojas, I; Sanchez-Mejias, E; Garrido-Martín, D; Gonzalez-Palma, L; Jimenez, S; Pino-Angeles, A; Cruz-Gamero, JM; Mendoza, S; Alarcón-Martín, E; Muñoz-Castro, C; Real, LM; Tenao, JJ; Polvillo, R; Govantes, F; Lopez, A; Royo-Aguado, JL; Navarro,...